Widely read:
Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations 2015 this is to inform you that the Board of Directros have at their Meeting held today 05/Sept/2026 inter alia approved to acquire 24 23 675.64 equity shares of the common stock of MedTherapy Biotechnology Inc USA incorporated under the laws of the State of Delaware equivalent to 9.50% of the issued and outstanding share capital of the Company. Mr. Hemal Mehta and Mr. Sachin Mehta Promoters of the Company shall acquire 3 82 685.63 equity shares each of common stock equivalent to 1.50% each of the issued and outstanding equity share capital of the Company. Additional details in the letter attached herewith.
Ask Value Research 
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.
